tetano
Editor, Senior Moderator
J Korean Med Sci
. 2021 Mar 8;36(9):e64.
doi: 10.3346/jkms.2021.36.e64.
Comparison of Serologic Response of Hospitalized COVID-19 Patients Using 8 Immunoassays
Sun Min Lee[SUP] 1 2 3 [/SUP], In Suk Kim[SUP] 1 2 4 [/SUP], Seungjin Lim[SUP] 2 5 [/SUP], Su Jin Lee[SUP] 2 5 [/SUP], Won Joo Kim[SUP] 1 2 [/SUP], Kyung Hwa Shin[SUP] 3 6 [/SUP], Soo Young Moon[SUP] 7 [/SUP], Chulhun L Chang[SUP] 1 2 3 [/SUP]
Affiliations
Abstract
Background: In Korea, there were issues regarding the use of immunoassays for anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies to detect infection. So, we compared antibody results of eight kinds of commercial immunoassays using clinical remnant specimens.
Methods: We compared the results of several immunoassay kits tested on 40 serum samples from 15 confirmed patients and 86 remnant serum samples from clinical laboratory. Eight kinds of IVD kits-four enzyme-linked immunosorbent assay, two lateral flow rapid immunochromatographic assays, and two chemiluminescent immunoassays with one RUO kit were tested.
Results: Among 40 serum samples from 15 coronavirus disease 2019 (COVID-19) patients, 35 yielded at least one positive result for detecting antibodies in the combined assessment. There were inconsistent results in 12 (28%) samples by single immunoassay. Forty samples collected in 2019 before the first COVID-19 Korean case showed negative results except for one equivocal result.
Conclusion: The discrepant results obtained with different immunoassay kits in this study show that serological assessment of SARS-CoV-2 by a single immunoassay requires caution not only in detecting infection but also in assessing immunologic status.
Keywords: Antibodies; COVID-19; ELISA; Immunoassay; Korea; SARS-CoV-2.
. 2021 Mar 8;36(9):e64.
doi: 10.3346/jkms.2021.36.e64.
Comparison of Serologic Response of Hospitalized COVID-19 Patients Using 8 Immunoassays
Sun Min Lee[SUP] 1 2 3 [/SUP], In Suk Kim[SUP] 1 2 4 [/SUP], Seungjin Lim[SUP] 2 5 [/SUP], Su Jin Lee[SUP] 2 5 [/SUP], Won Joo Kim[SUP] 1 2 [/SUP], Kyung Hwa Shin[SUP] 3 6 [/SUP], Soo Young Moon[SUP] 7 [/SUP], Chulhun L Chang[SUP] 1 2 3 [/SUP]
Affiliations
- PMID: 33686810
- DOI: 10.3346/jkms.2021.36.e64
Abstract
Background: In Korea, there were issues regarding the use of immunoassays for anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies to detect infection. So, we compared antibody results of eight kinds of commercial immunoassays using clinical remnant specimens.
Methods: We compared the results of several immunoassay kits tested on 40 serum samples from 15 confirmed patients and 86 remnant serum samples from clinical laboratory. Eight kinds of IVD kits-four enzyme-linked immunosorbent assay, two lateral flow rapid immunochromatographic assays, and two chemiluminescent immunoassays with one RUO kit were tested.
Results: Among 40 serum samples from 15 coronavirus disease 2019 (COVID-19) patients, 35 yielded at least one positive result for detecting antibodies in the combined assessment. There were inconsistent results in 12 (28%) samples by single immunoassay. Forty samples collected in 2019 before the first COVID-19 Korean case showed negative results except for one equivocal result.
Conclusion: The discrepant results obtained with different immunoassay kits in this study show that serological assessment of SARS-CoV-2 by a single immunoassay requires caution not only in detecting infection but also in assessing immunologic status.
Keywords: Antibodies; COVID-19; ELISA; Immunoassay; Korea; SARS-CoV-2.